Caris Life Sciences launched Caris ChromoSeq, a combined whole-genome sequencing and whole-transcriptome assay intended to improve comprehensive genomic evaluation of myeloid malignancies. The company said the test provides approximately 250x genomic read depth and 40 million transcriptome reads from bone marrow aspirates or peripheral blood. Parse Biosciences also introduced Evercode Whole Transcriptome FFPE kits, enabling whole-transcriptome single-cell RNA sequencing from formalin-fixed paraffin-embedded samples. Parse said the kits use split-pool combinatorial barcoding and reverse transcription-based RNA capture designed for compromised RNA, with applications across oncology and neuroscience. Together, the product launches reflect a push to standardize high-resolution genomic and transcriptomic profiling while expanding compatibility with common clinical sample types like FFPE. For labs and trialists, assay choice can materially affect turnaround time and the quality of downstream biomarker analyses.